Heparinoid
Brand names: Hirudoid
Heparinoid is a topical preparation used to relieve superficial soft-tissue conditions such as bruising, superficial thrombophlebitis and haematomas.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a heparin-like polysulphated mucopolysaccharide thought to have local anti-inflammatory and anti-oedematous actions that aid resorption of superficial extravasated blood and fluid.
Prescribing in practice
- It is for external use on intact skin only and should not be applied to broken skin, open wounds, mucous membranes or near the eyes.
- Discontinue if local irritation or a hypersensitivity reaction occurs.
- It is intended for superficial conditions and is not a treatment for deep vein thrombosis or other conditions requiring systemic anticoagulation.
Monitoring
No laboratory monitoring is required; review symptomatic response and local skin tolerability.
Counselling the patient
- Apply gently to the affected area on unbroken skin and avoid the eyes and open wounds.
- Stop if the skin becomes irritated or a rash develops.
- Seek medical advice if a limb becomes painful, swollen or hot, which may indicate a deeper clot.
Evidence & guidelines
Topical heparinoids are an established symptomatic option for superficial bruising and thrombophlebitis, used as supportive rather than definitive therapy.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD